Aureus Asset Management LLC Has $2.87 Million Position in Danaher Co. (NYSE:DHR)

Aureus Asset Management LLC reduced its holdings in Danaher Co. (NYSE:DHR) by 21.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 10,304 shares of the conglomerate’s stock after selling 2,816 shares during the quarter. Aureus Asset Management LLC’s holdings in Danaher were worth $2,865,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in Danaher in the second quarter valued at approximately $25,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the third quarter valued at approximately $40,000. Finally, FSA Wealth Management LLC bought a new stake in Danaher in the third quarter valued at approximately $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Stifel Nicolaus upped their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. Raymond James lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Finally, KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Up 0.4 %

Danaher stock opened at $239.69 on Monday. The company has a market cap of $173.12 billion, a P/E ratio of 45.74, a price-to-earnings-growth ratio of 4.41 and a beta of 0.85. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company has a fifty day simple moving average of $254.59 and a 200 day simple moving average of $259.41. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. Research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.